Story perspectives

U.S. to Supply Lenacapavir HIV Drug at Cost, Aiming for 2 Million Lives

9/5/2025

35 3

Summary

Story summary

The U.S. State Department plans to supply Gilead Sciences' HIV drug lenacapavir "at cost" in high-burden countries.
The initiative targets reaching 2 million people within three years.
Gilead will provide the drug to the Global Fund and PEPFAR program without profit.

1 of 1

Story summary

The U.S. State Department plans to supply Gilead Sciences' HIV drug lenacapavir "at cost" in high-burden countries.
The initiative targets reaching 2 million people within three years.
Gilead will provide the drug to the Global Fund and PEPFAR program without profit.